Integra Lifesciences (IART)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 235,048 | 232,186 | 217,914 | 239,104 | 246,375 |
| Marketable Securities | 28,693 | 35,693 | 35,694 | 34,191 | 27,192 |
| Receivables | 278,849 | 262,160 | 284,507 | 252,446 | 272,370 |
| Inventories | 492,735 | 489,106 | 465,127 | 445,418 | 429,090 |
| Other current assets | 28,130 | 30,326 | 36,121 | 32,214 | 29,653 |
| TOTAL | $1,159,544 | $1,143,582 | $1,142,828 | $1,107,247 | $1,081,681 |
| Non-Current Assets | |||||
| PPE Net | 444,335 | 437,367 | 434,816 | 422,913 | 405,723 |
| Intangibles | 1,749,820 | 1,775,344 | 1,804,507 | 2,292,921 | 2,304,540 |
| Other Non-Current Assets | 248,302 | 290,159 | 285,754 | 229,670 | 245,480 |
| TOTAL | $2,442,457 | $2,502,870 | $2,525,077 | $2,945,504 | $2,955,743 |
| Total Assets | $3,602,001 | $3,646,452 | $3,667,905 | $4,052,751 | $4,037,424 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 87,800 | 0 | 574,628 | 573,899 | 573,170 |
| Accounts payable and accrued liabilities | 95,726 | 92,305 | 92,835 | 91,296 | 82,502 |
| Accrued Expenses | 204,572 | 207,847 | 198,314 | 189,797 | 207,525 |
| Other current liabilities | 11,463 | 11,326 | 11,103 | 10,539 | 10,483 |
| TOTAL | $455,981 | $364,054 | $929,806 | $918,452 | $922,126 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,729,556 | 1,792,351 | 1,226,942 | 1,230,641 | 1,196,017 |
| Other Non-Current Liabilities | 367,337 | 394,188 | 412,432 | 321,938 | 313,168 |
| TOTAL | $2,102,557 | $2,244,824 | $1,699,438 | $1,610,160 | $1,570,018 |
| Total Liabilities | $2,558,538 | $2,608,878 | $2,629,244 | $2,528,612 | $2,492,144 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 77,937 | 77,892 | 77,911 | 77,712 | 77,219 |
| Common Shares | 923 | 923 | 923 | 921 | 916 |
| Retained earnings | 423,441 | 425,145 | 430,549 | 914,622 | 939,915 |
| Other shareholders' equity | -30,287 | -32,000 | -30,941 | -24,485 | -27,982 |
| TOTAL | $1,043,463 | $1,037,574 | $1,038,661 | $1,524,139 | $1,545,280 |
| Total Liabilities And Equity | $3,602,001 | $3,646,452 | $3,667,905 | $4,052,751 | $4,037,424 |